Aytu Biopharma (AYTU) Convertible Debt (2015 - 2016)
Aytu Biopharma's (AYTU) quarterly Convertible Debt came in at $9797.0 in Q1 2016, down 99.8% on a QoQ basis from $4.9 million in Q4 2015.
Aytu Biopharma (AYTU) Convertible Debt (2015 - 2016) Analysis & Trends
Aytu Biopharma (AYTU) has 2 years of Convertible Debt data on file, last reported at $9797.0 in Q1 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Aytu Biopharma | 1.43 Mn | -25.28 Mn | 7.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2016 | 9,797.00 |
| Dec 31, 2015 | 4.92 Mn |
| Sep 30, 2015 | 4.83 Mn |